
The American government is steadily placing more orders for smallpox vaccines in the hands of the Danish biotech company Bavarian Nordic, a sign that even more orders could be underway this year.
That’s the assessment from Bavarian Nordic CEO, Anders Hedegaard, following a recent analysis from the major bank Nordea, in which they are extremely positive towards the company and see great potential in the share.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app